SunTrust reports that a pediatric hematology expert views the 24% levels of anti-sickling T87Q HbA in the sickle cell patient taking bluebird's LentiGlobin as "exciting." The expert views the 31.6% functional or anti-sickling Hb level as meaningful, since survival benefits are seen with patients who achieve an increase of even 10%+, according to the firm. The expert expects the patient's T87Q HbA levels to be higher when the company reports new data next month. The firm recommends the stock ahead of the presentation of that data, expected to occur on June 13.